 <h1>Taliglucerase alfa Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of taliglucerase alfa include:</b> arthralgia, back pain, and headache. <b>Other side effects include:</b> asthenia, chest discomfort, chest pain, fatigue, increased blood pressure, urticaria, erythema of skin, and flushing.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to taliglucerase alfa: intravenous powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, taliglucerase alfa may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking taliglucerase alfa:</p><p>
<i>More common</i>
</p><ul>
<li>Chest tightness</li>
<li>dizziness</li>
<li>feeling of warmth</li>
<li>hives or welts, itching, or skin rash</li>
<li>irritation in the throat</li>
<li>large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>nausea or vomiting</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
<li>redness of the skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blurred vision</li>
<li>confusion</li>
<li>cough</li>
<li>difficulty with swallowing</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>fast heartbeat</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>sweating</li>
<li>unusual tiredness or weakness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of taliglucerase alfa may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>difficulty with moving</li>
<li>feeling of warmth</li>
<li>headache</li>
<li>muscle pain or stiffness</li>
<li>pain in the joints</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to taliglucerase alfa: intravenous powder for injection</i></p><h3>General</h3><p>The most frequently reported side effects were headache, arthralgia, pain in extremity, fatigue, nausea, dizziness, pruritus, flushing, abdominal pain, vomiting, back pain, and rash.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Vomiting, abdominal pain</p>
<p><b>Common</b> (1% to 10%): Nausea, diarrhea</p>
<p><b>Frequency not reported</b>: Gastrointestinal inflammation<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very common</b> (10% or more): Hypersensitivity reactions (including anaphylaxis; 29%)</p>
<p><b>Frequency not reported</b>: Type III immune-mediated fixed drug eruption</p>
<p><b>Postmarketing reports</b>: Anaphylaxis<sup>[Ref]</sup></p><p>In clinical trials, hypersensitivity reactions (including anaphylaxis) were reported in 29% of patients; these reactions occurred up to 3 hours after the start of infusion.  Serious hypersensitivity reactions (including anaphylaxis) were reported in some patients.  In clinical trials, 3% of patients had signs/symptoms consistent with anaphylaxis; these reactions occurred during the infusion.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (up to 13%), pain in extremity (up to 10%)</p>
<p><b>Common</b> (1% to 10%): Back pain, bone pain</p>
<p><b>Frequency not reported</b>: Muscle spasms<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Development of anti-drug antibodies (up to 53%), neutralizing antibodies detected (10.3%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 19%)</p>
<p><b>Common</b> (1% to 10%): Dizziness, paresthesia</p>
<p><b>Frequency not reported</b>: Tremor<sup>[Ref]</sup></p><h3>Other</h3><p>Infusion-related reactions occurred most often within 24 hours of the infusion and consisted of arthralgia, headache, vomiting, flushing, pruritus, pain in extremity, pulmonary hypertension, diarrhea, chest discomfort, feeling hot, muscle spasms, tremor, throat irritation, erythema, and rash.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Fatigue, flushing, peripheral edema, infusion reaction, weight increased</p>
<p><b>Frequency not reported</b>: Chest discomfort, feeling hot<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, erythema, rash, urticaria<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Throat irritation, rhinorrhea, sneezing</p>
<p><b>Frequency not reported</b>: Pulmonary hypertension<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1%to 10%): ALT increased<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion site pain<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Eye pruritus, eye swelling, lacrimation increased<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Elelyso (taliglucerase alfa)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about taliglucerase alfa</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>En Espa√±ol</li>
<li>Drug class: lysosomal enzymes</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Taliglucerase alfa Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Elelyso</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Gaucher Disease</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to taliglucerase alfa: intravenous powder for injection</i></p><h3>General</h3><p>The most frequently reported side effects were headache, arthralgia, pain in extremity, fatigue, nausea, dizziness, pruritus, flushing, abdominal pain, vomiting, back pain, and rash.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Vomiting, abdominal pain</p><p><b>Common</b> (1% to 10%): Nausea, diarrhea</p><p><b>Frequency not reported</b>: Gastrointestinal inflammation<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Very common</b> (10% or more): Hypersensitivity reactions (including anaphylaxis; 29%)</p><p><b>Frequency not reported</b>: Type III immune-mediated fixed drug eruption</p><p><b>Postmarketing reports</b>: Anaphylaxis<sup>[Ref]</sup></p><p>In clinical trials, hypersensitivity reactions (including anaphylaxis) were reported in 29% of patients; these reactions occurred up to 3 hours after the start of infusion.  Serious hypersensitivity reactions (including anaphylaxis) were reported in some patients.  In clinical trials, 3% of patients had signs/symptoms consistent with anaphylaxis; these reactions occurred during the infusion.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (up to 13%), pain in extremity (up to 10%)</p><p><b>Common</b> (1% to 10%): Back pain, bone pain</p><p><b>Frequency not reported</b>: Muscle spasms<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Development of anti-drug antibodies (up to 53%), neutralizing antibodies detected (10.3%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 19%)</p><p><b>Common</b> (1% to 10%): Dizziness, paresthesia</p><p><b>Frequency not reported</b>: Tremor<sup>[Ref]</sup></p><h3>Other</h3><p>Infusion-related reactions occurred most often within 24 hours of the infusion and consisted of arthralgia, headache, vomiting, flushing, pruritus, pain in extremity, pulmonary hypertension, diarrhea, chest discomfort, feeling hot, muscle spasms, tremor, throat irritation, erythema, and rash.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Fatigue, flushing, peripheral edema, infusion reaction, weight increased</p><p><b>Frequency not reported</b>: Chest discomfort, feeling hot<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, erythema, rash, urticaria<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Throat irritation, rhinorrhea, sneezing</p><p><b>Frequency not reported</b>: Pulmonary hypertension<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1%to 10%): ALT increased<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion site pain<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Eye pruritus, eye swelling, lacrimation increased<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Elelyso (taliglucerase alfa)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2>More about taliglucerase alfa</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>En Espa√±ol</li>
<li>Drug class: lysosomal enzymes</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Taliglucerase alfa Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Gaucher Disease</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>